Home Cart Sign in  
Chemical Structure| 1228013-15-7 Chemical Structure| 1228013-15-7

Structure of CC-115
CAS No.: 1228013-15-7

Chemical Structure| 1228013-15-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CC-115 is an inhibitor of mTOR and DNA-PK with IC50 of 21 and 13 nM respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CC-115

CAS No. :1228013-15-7
Formula : C16H16N8O
M.W : 336.35
SMILES Code : O=C1CN=C2C(N1CC)=NC(C3=C(C)N=C(C4=NN=CN4)C=C3)=CN2
MDL No. :MFCD29036965
InChI Key :GMYLVKUGJMYTFB-UHFFFAOYSA-N
Pubchem ID :58298318

Safety of CC-115

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of CC-115

DNA
PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • DNA-PK

    DNA-PK, IC50:0.013 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Multiple myeloma cells 1.5 nM to 10 µM 72 h CC-115 showed dose-dependent growth inhibition in multiple myeloma cells, and its effect was superior to the specific TORK inhibitor CC-223. PMC9892823
HCT 116 cells 0.1 µM to 3.5 µM 4 h CC-115 induced a dose-dependent increase in NMD transcripts in HCT 116 cells, indicating inhibition of SMG1-mediated NMD. PMC9892823
CAL33 1 µM 24 h CC-115 + IR treatment led to an elevation in G2/M arrest, increased cell death, and a synergistic reduction in cell proliferation, though the effect was notably lower compared to the AZD7648 + IR- treated group. PMC10887161
UM-SCC-47 1 µM 24 h CC-115 + IR treatment led to an elevation in G2/M arrest, increased cell death, and a synergistic reduction in cell proliferation, though the effect was notably lower compared to the AZD7648 + IR- treated group. PMC10887161
LNCaP-AR 1 μM 24 h reduced invasion and migration of CRPC cells PMC6744969
C4-2B 1 μM 24 h reduced invasion and migration of CRPC cells PMC6744969
LNCaP-AR-enza-res 1 μM 24 h reduced invasion and migration of enzalutamide-resistant CRPC cells PMC6744969
C4-2 0–25 μM 6 days Assessment of CC-115 in hormone-sensitive and castration-resistant prostate cancer models showed that CC-115 reduced cell viability in a dose-dependent manner and induced apoptosis. PMC6744985
22Rv1 0–25 μM 6 days Assessment of CC-115 in hormone-sensitive and castration-resistant prostate cancer models showed that CC-115 reduced cell viability in a dose-dependent manner and induced apoptosis. PMC6744985
Healthy donor skin fibroblasts (SBLF7) 0.1–25 μM 48 h To study the effect of CC-115 on cell death, results showed that cell death increased linearly with increasing concentration of CC-115. PMC7730287
Melanoma cells (ARPA) 0.1–25 μM 48 h To study the effect of CC-115 on cell death, results showed that melanoma cells were more sensitive to CC-115, with cell death reaching saturation at higher concentrations. PMC7730287
Melanoma cells (HV18MK) 0.1–25 μM 48 h To study the effect of CC-115 on cell death, results showed that melanoma cells were more sensitive to CC-115, with cell death reaching saturation at higher concentrations. PMC7730287
LOU-NH91 25.10 μM 72 h Assessed the IC50 value of CC-115 on LOU-NH91 cells, showing synergistic effects with carboplatin PMC9452486
H596 0.68 μM 72 h Assessed the IC50 value of CC-115 on H596 cells, showing synergistic effects with carboplatin PMC9452486
H1975 0.31 μM 72 h Assessed the IC50 value of CC-115 on H1975 cells, showing synergistic effects with carboplatin PMC9452486
TM00244 0.43 μM 72 h Assessed the IC50 value of CC-115 on TM00244 cells, showing synergistic effects with carboplatin PMC9452486
H226 0.95 μM 72 h Assessed the IC50 value of CC-115 on H226 cells, showing synergistic effects with carboplatin PMC9452486
Calu-1 1.38 μM 72 h Assessed the IC50 value of CC-115 on Calu-1 cells, showing synergistic effects with carboplatin PMC9452486
Atmfl/fl; LSL-KrasG12D/+; Ptf1aCre/+ (AKC) cells 30 nM 6 h To evaluate the effect of CC-115 on DNA replication dynamics PMC7948173
ATM+/Δ MIA PaCa-2 cells 30 nM 48 h To evaluate the synergistic effect of CC-115 in combination with PARPi and ATRi PMC7948173
LOU-NH91 0.2 μM 72 h CC-115 in combination with carboplatin showed synergistic effects in LOU-NH91 cells, significantly inhibiting cell viability. PMC9452486
Calu-1 0.4 μM 72 h CC-115 in combination with carboplatin showed synergistic effects in Calu-1 cells, significantly inhibiting cell viability. PMC9452486
H226 0.4 μM 72 h CC-115 in combination with carboplatin showed synergistic effects in H226 cells, significantly inhibiting cell viability. PMC9452486

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Multiple myeloma xenograft model Oral 5 mg/kg Once daily until day 36 CC-115 showed significant antitumor activity in the multiple myeloma xenograft model, with a significant reduction in tumor volume and good tolerability. PMC9892823
CB17-SCID mice LNCaP-AR xenograft model oral 2 mg/kg 5 times per week for 6 weeks significantly delayed tumor growth PMC6744969
CB17 SCID mice Castration-resistant prostate cancer model Oral 2 mg/kg Once daily for 39 days Evaluation of the tumor growth inhibitory effects of CC-115 in combination with Enzalutamide in castration-resistant prostate cancer models showed that the combination treatment significantly increased tumor doubling time and improved survival rates. PMC6744985
mice LUSC PDX models oral gavage and I.P. injection 1 mg/kg once weekly for four weeks Evaluated the antitumor effect of CC-115 in combination with carboplatin and paclitaxel on LUSC PDX models, showing significant tumor growth inhibition and prolonged survival PMC9452486
Mice Subcutaneous tumor model Intraperitoneal injection 2.5 mg/kg Once daily for 17 days To evaluate the inhibitory effect of CC-115 in combination with PARPi and ATRi on the growth of ATM-deficient PDAC tumors PMC7948173
Mice LUSC patient-derived xenograft models Oral gavage (CC-115), Intraperitoneal injection (carboplatin and paclitaxel) 1 mg/kg Once weekly (carboplatin and paclitaxel), daily (CC-115), for four weeks CC-115 in combination with carboplatin and paclitaxel significantly inhibited tumor growth and extended survival in mice. PMC9452486

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01353625 Glioblastoma Multiforme|Squamo... More >>us Cell Carcinoma of Head and Neck|Prostate Cancer|Ewing's Osteosarcoma|Chronic Lymphocytic Leukemia|Neoplasm Metastasis Less << PHASE1 COMPLETED 2021-03-12 Cedars-Sinai Medical Center, L... More >>os Angeles, California, 90048, United States|UCLA, Los Angeles, California, 90095, United States|University of California, San Francisco Comprehensive Cancer Center and Cancer Research Institiute, San Francisco, California, 94115, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Henry Ford Medical Center - New Center One, Detroit, Michigan, 48202, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, 37203, United States|Mary Crowley Medical Research Center, Dallas, Texas, 75201, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77303, United States|Gustave Roussy, Villejuif Cedex, 94805, France|Uniklinik Koln, Koeln, 50937, Germany|Universitatsklinikum Wurzburg, Würzburg, 97070, Germany|Hospital Val d'Hebron, Barcelona, 08035, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, 28050, Spain|Hospital de Donosti, San Sebastián (Guipuzcoa), 20014, Spain|Hospital Virgen del Rocio, Sevilla, 41013, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.97mL

0.59mL

0.30mL

14.87mL

2.97mL

1.49mL

29.73mL

5.95mL

2.97mL

References

 

Historical Records

Categories